Evidence map›Paper›PMID 35114114›Full record

ArticleThe Lancet. Oncology2022

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic.

Georg Pfeiler, Angela DeMichele, Amylou C Dueck, Christian Fesl, Michael Gnant, Erica L Mayer

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Georg PfeilerDepartment of Gynecology, Medical University of Vienna, Vienna, Austria.
Angela DeMichelePerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Amylou C DueckAlliance Statistics and Data Center, Mayo Clinic, Phoenix, AZ, USA.
Christian FeslAustrian Breast and Colorectal Cancer Study Group, Vienna, Austria.
Michael GnantComprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Erica L MayerBreast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: erica_mayer@dfci.harvard.edu.
Austrian Breast & Colorectal Cancer Study Group · ATComprehensive Cancer Center Vienna · ATMayo Clinic in Florida · USMedical University of Vienna · ATUniversity of Pennsylvania · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
NCI NIH HHS P30 CA015083NCI NIH HHS UG1 CA233180
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HumansPandemicsSARS-CoV-2CDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6

Identifiers

PMID35114114
PMCPMC8803349
OpenAlexW4210425913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.